Latest news with #Repligen
Yahoo
a day ago
- Business
- Yahoo
Three Stocks That Could Be Undervalued By Market Estimates In July 2025
Over the last 7 days, the United States market has remained flat, yet it has shown a robust increase of 14% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying stocks that are potentially undervalued can provide opportunities for investors seeking to capitalize on discrepancies between market estimates and intrinsic value. Top 10 Undervalued Stocks Based On Cash Flows In The United States Name Current Price Fair Value (Est) Discount (Est) Robert Half (RHI) $41.80 $82.59 49.4% Repligen (RGEN) $114.80 $224.90 49% Hesai Group (HSAI) $20.86 $41.09 49.2% Freshpet (FRPT) $68.12 $133.26 48.9% Definitive Healthcare (DH) $3.99 $7.80 48.8% Carter Bankshares (CARE) $18.10 $35.50 49% Camden National (CAC) $42.29 $83.80 49.5% Atlantic Union Bankshares (AUB) $32.98 $65.45 49.6% ACNB (ACNB) $43.36 $85.03 49% Acadia Realty Trust (AKR) $18.61 $36.69 49.3% Click here to see the full list of 175 stocks from our Undervalued US Stocks Based On Cash Flows screener. Let's review some notable picks from our screened stocks. MetroCity Bankshares Overview: MetroCity Bankshares, Inc. is the bank holding company for Metro City Bank, offering a range of banking products and services in the United States with a market cap of $744.26 million. Operations: MetroCity Bankshares generates its revenue through various segments, but specific segment details are not provided in the available text. Estimated Discount To Fair Value: 42.1% MetroCity Bankshares is trading at a significant discount to its estimated fair value, with shares priced at US$30.53 compared to a fair value estimate of US$52.73. Recent earnings reports show steady growth in net interest income and net income over the past year, despite minor charge-offs. The company's revenue and earnings are forecasted to grow significantly faster than the broader U.S. market, suggesting strong potential for future cash flow improvements. Upon reviewing our latest growth report, MetroCity Bankshares' projected financial performance appears quite optimistic. Get an in-depth perspective on MetroCity Bankshares' balance sheet by reading our health report here. Sportradar Group Overview: Sportradar Group AG, along with its subsidiaries, offers sports data services to the sports betting and media industries across various regions including Switzerland, the United States, and several other global markets, with a market cap of $9.04 billion. Operations: The company's revenue from data processing services amounts to €1.15 billion. Estimated Discount To Fair Value: 29.4% Sportradar Group is trading at US$29.8, significantly below its estimated fair value of US$42.23, indicating it may be undervalued based on cash flows. The company's earnings grew by a very large margin in the past year and are expected to grow significantly faster than the U.S. market over the next three years, despite slower revenue growth projections. A recent partnership with DAZN enhances its market position and potential cash flow through exclusive data distribution rights for major soccer events. Our expertly prepared growth report on Sportradar Group implies its future financial outlook may be stronger than recent results. Dive into the specifics of Sportradar Group here with our thorough financial health report. V.F Overview: V.F. Corporation, along with its subsidiaries, provides branded apparel, footwear, and accessories for men, women, and children across the Americas, Europe, and the Asia-Pacific regions with a market cap of approximately $4.78 billion. Operations: The company's revenue segments include Work at $833.10 million, Active at $3.10 billion, and Outdoor at $5.58 billion. Estimated Discount To Fair Value: 11.9% V.F. Corporation, trading at US$12.45, is below its estimated fair value of US$14.13, suggesting undervaluation based on cash flows. Despite a recent net loss reduction and expected significant earnings growth, the company's debt coverage by operating cash flow remains weak. Revenue growth forecasts are modest compared to the market average. Recent financial restructuring includes an amendment to its $2.25 billion revolving credit facility, indicating ongoing efforts to strengthen financial stability amidst executive changes. The growth report we've compiled suggests that V.F's future prospects could be on the up. Take a closer look at V.F's balance sheet health here in our report. Turning Ideas Into Actions Take a closer look at our Undervalued US Stocks Based On Cash Flows list of 175 companies by clicking here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Want To Explore Some Alternatives? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include MCBS SRAD and VFC. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
5 days ago
- Business
- Yahoo
1 Safe-and-Steady Stock on Our Buy List and 2 We Turn Down
A stock with low volatility can be reassuring, but it doesn't always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. Choosing the wrong investments can cause you to fall behind, which is why we started StockStory - to separate the winners from the losers. Keeping that in mind, here is one low-volatility stock that could succeed under all market conditions and two that may not deliver the returns you need. Two Stocks to Sell: Calavo (CVGW) Rolling One-Year Beta: 0.89 A trailblazer in the avocado industry, Calavo Growers (NASDAQ:CVGW) is a pioneering California-based provider of high-quality avocados and other fresh food products. Why Do We Steer Clear of CVGW? Annual revenue declines of 15.8% over the last three years indicate problems with its market positioning Projected sales decline of 1.8% over the next 12 months indicates demand will continue deteriorating Gross margin of 10.5% is an output of its commoditized products Calavo's stock price of $26.66 implies a valuation ratio of 14x forward P/E. Read our free research report to see why you should think twice about including CVGW in your portfolio, it's free. Repligen (RGEN) Rolling One-Year Beta: 0.95 With over 13 strategic acquisitions since 2012 to build its comprehensive bioprocessing portfolio, Repligen (NASDAQ:RGEN) develops and manufactures specialized technologies that improve the efficiency and flexibility of biological drug manufacturing processes. Why Is RGEN Risky? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 16.9 percentage points Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results At $114.32 per share, Repligen trades at 59x forward P/E. To fully understand why you should be careful with RGEN, check out our full research report (it's free). One Stock to Buy: MercadoLibre (MELI) Rolling One-Year Beta: 0.87 Originally started as an online auction platform, MercadoLibre (NASDAQ:MELI) is a one-stop e-commerce marketplace and fintech platform in Latin America. Why Is MELI a Good Business? Unique Active Buyers have grown by 20.8% annually, allowing for more profitable cross-selling opportunities if it can build complementary products and features Grip over its ecosystem is highlighted by its ability to grow engagement while increasing the average revenue per user by 15.4% annually Robust free cash flow margin of 31.1% gives it many options for capital deployment, and its improved cash conversion implies it's becoming a less capital-intensive business MercadoLibre is trading at $2,319 per share, or 23.3x forward EV/EBITDA. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Stocks We Like Even More Trump's April 2024 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines. Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
25-06-2025
- Business
- Yahoo
5 Insightful Analyst Questions From Repligen's Q1 Earnings Call
Repligen's first quarter results for 2025 saw revenue and adjusted profits exceed Wall Street expectations, but the market reacted negatively, reflecting investor caution. Management attributed growth to strong demand across its protein, chromatography, and analytics product lines, as well as robust order momentum in biopharma manufacturing. CEO Olivier Loeillot highlighted that "orders were up high teens year on year with all franchises growing double digits," and noted particularly strong performance from consumables and proteins. However, capital equipment sales faced headwinds due to timing and customer delays, while small biotech sales softened, highlighting ongoing uncertainty in that segment. Is now the time to buy RGEN? Find out in our full research report (it's free). Revenue: $169.2 million vs analyst estimates of $164.3 million (10.4% year-on-year growth, 3% beat) Adjusted EPS: $0.39 vs analyst estimates of $0.35 (11.4% beat) Adjusted EBITDA: $32.7 million vs analyst estimates of $28.78 million (19.3% margin, 13.6% beat) The company lifted its revenue guidance for the full year to $707.5 million at the midpoint from $697.5 million, a 1.4% increase Management lowered its full-year Adjusted EPS guidance to $1.67 at the midpoint, a 2.3% decrease Operating Margin: 3.9%, up from 2.4% in the same quarter last year Organic Revenue rose 10.7% year on year (-12.5% in the same quarter last year) Market Capitalization: $6.75 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Rachel Vatnsdal (JPMorgan) asked whether tariffs led to order pull-forward and about the sustainability of CDMO order strength. CEO Olivier Loeillot replied there was no evidence of customers accelerating purchases and that CDMO growth was broad-based, especially in ATF consumables. Dan Arias (Stifel) inquired about emerging modalities and potential impacts from FDA changes. Loeillot confirmed new modalities revenue and orders rose, and reported no signs of trial disruptions or slowdowns from regulatory changes. Puneet Souda (Leerink Partners) questioned the clinical versus commercial revenue mix's sustainability and the integration of 908 Devices. Loeillot explained the mix remains stable but is gradually shifting commercial, and integration efforts are focused on R&D and commercial synergy. Jacob Johnson (William Blair) asked about small biotech trends. Loeillot acknowledged sales to small biotech declined due to weak funding, but this segment now represents less than 10% of Repligen's business. Justin Bowers (Deutsche Bank) asked about the impact of biopharma onshoring and margin outlook. Loeillot highlighted that increased U.S. manufacturing capacity could be a tailwind, and Garland noted Q1 gross margin benefited from product mix that is unlikely to repeat. In the coming quarters, the StockStory team will be watching (1) the pace of adoption for new analytics and mixing technologies, (2) the trajectory of order growth among large pharma, CDMO, and emerging modalities, and (3) signs of stabilization or recovery in small biotech and China segments. Progress on integrating recent acquisitions and managing tariff-related risks will also be important markers for execution. Repligen currently trades at $123.96, down from $143.71 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
Globe and Mail
22-05-2025
- Business
- Globe and Mail
Repligen Corporation to Present at William Blair Growth Conference
WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45 th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3 rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are 'inspiring advances in bioprocessing' for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at and follow us on LinkedIn.
Yahoo
22-05-2025
- Business
- Yahoo
Repligen Corporation to Present at William Blair Growth Conference
WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at and will be available for replay for a limited period of time following the event. About Repligen CorporationRepligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are 'inspiring advances in bioprocessing' for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at and follow us on LinkedIn. Repligen Contact: Jacob JohnsonVP, Investor Relations(781) 419-0204investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
